China National Medicines Corporation Ltd.
600511
Rank in Stocks
#4956
China National Medicines Corporation Ltd., in conjunction with its various... China National Medicines Corporation Ltd., in conjunction with its various operating entities, is a prominent player in the distribution of pharmaceutical goods across China. The enterprise's scope extends to the production and commercialization of innovative as well as pre-existing drug formulations. Additionally, it markets both traditional Chinese patent remedies and modern Western medications, alongside a range of medical apparatus. Complementing these activities, the firm delivers warehousing solutions and acts as an agent for import and export transactions. Its diverse clientele encompasses hospitals, retail pharmacies, and other healthcare organizations. Established in 1999, the company maintains its principal office in Beijing, China.
Share Price
$3.90
Market Cap
$2.94B
Change (1 day)
-1.46%
Change (1 year)
-3.02%
Country
CN
Trade China National Medicines Corporation Ltd. (600511)
Category
Healthcare
Revenue for China National Medicines Corporation Ltd. (600511)
Revenue in Jun 2026 TTM: $7.76B
According to China National Medicines Corporation Ltd. latest financial reports the company's current revenue (TTM) is $7.76B. In 2023 the company made a revenue of $7.02B an increase over the revenue in the year 2022 that was $6.60B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for China National Medicines Corporation Ltd. from 2000 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $7.76B | 11.97% |
| 2024 | $6.93B | -1.26% |
| 2023 | $7.02B | 6.44% |
| 2022 | $6.60B | -9.78% |
| 2021 | $7.31B | 18.28% |
| 2020 | $6.18B | -3.59% |
| 2019 | $6.41B | 13.84% |
| 2018 | $5.63B | 0.99% |
| 2017 | $5.58B | 11.87% |
| 2016 | $4.99B | 168.02% |
| 2015 | $1.86B | -0.15% |
| 2014 | $1.86B | 12.08% |
| 2013 | $1.66B | 20.63% |
| 2012 | $1.38B | 23.34% |
| 2011 | $1.12B | 24.59% |
| 2010 | $896.61M | 17.84% |
| 2009 | $760.87M | 18.39% |
| 2008 | $642.69M | 31.31% |
| 2007 | $489.45M | 36.11% |
| 2006 | $359.59M | 24.36% |
| 2005 | $289.14M | 32.86% |
| 2004 | $217.63M | 22.35% |
| 2003 | $177.87M | 20.30% |
| 2002 | $147.86M | 0.22% |
| 2001 | $147.54M | 11.05% |
| 2000 | $132.86M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $410.98B | 5,194.83% |
US
|
|
| - | - |
US
|
|
| $254.25B | 3,175.56% |
US
|
|
| - | - |
US
|
|
| $7.64B | -1.55% |
AU
|
